Emergent Interacting Phases in the Strong Coupling Limit of Twisted M-Valley Moiré Systems: Application to SnSe₂

We construct an interacting Wannier model for both AA-stacked and AB-stacked twisted SnSe2, revealing a rich landscape of correlated quantum phases. For the AA-stacked case, the system is effectively described by a three-orbital triangular lattice model, where each orbital corresponds to a valley and exhibits an approximate one-dimensional hopping structure due to a new momentum-space non-symmorphic symmetry. By exploring the interacting phase diagram using a combination of theoretical methods, including Hartree-Fock mean-field theory and exact solutions of the spin model in certain limits, we identify several exotic quantum phases. These include a dimerized phase with finite residual entropy, valence bond solids, and quantum paramagnetism. In the AB-stacked case, the system realizes an interacting kagome lattice model, where the Wannier orbitals associated with the three valleys form three sublattices. In the strong coupling regime, we use cluster mean-field methods to demonstrate the emergence of a classical spin liquid phase due to the frustrated lattice structure. The high tunability of the moiré system, which allows control over both the filling and interaction strength (via twist angle), renders twisted SnSe2 a versatile platform for realizing a wide range of exotic correlated quantum phases

The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Head and neck proton therapy in France: A missed opportunity or a challenge in front of us?

International audienceFollowing major advances of the best of photon-techniques such as intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and, to arrive soon, magnetic resonance (MR)-linac radiotherapy, there are still substantial opportunities in the treatment of head and neck cancers to further reduce the toxicity burden. Proton therapy represents another attractive option in this high-quality and highly competitive precision radiotherapy landscape. Proton therapy holds promises to reduce toxicities and to escalate the dose in radioresistant cases or cases where dose distribution is not satisfactory with photons. However, the selection of patients for proton therapy needs to be done using evidence-based medicine to build arguments in favor of personalized precision radiation therapy. Referral to proton therapy versus IMRT or SBRT should be registered (ProtonShare® platform) and envisioned in a formalized clinical research perspective through randomized trials. The use of an enrichment process using a model-based approach should be done to only randomize patients doomed to benefit from proton. To tackle such great opportunities, the French proton therapy challenge is to collaborate at the national and international levels, and to demonstrate that the extra-costs of treatment are worth clinically and economically in the short, mid, and long-term. In parallel to the clinical developments, there are still preclinical issues to be tackled (e.g., proton FLASH, mini-beams, combination with immunotherapy), for which the French Radiotransnet network offers a unique platform. The current article provides a personal view of the challenges and opportunities with a focus on clinical research and randomized trial requirements as well as the needs for strong collaborations at the national and international levels for PT in squamous cell carcinomas of the head and neck to dat